Tylenol Arthritis Pain Caplets on recall
This article was originally published in The Tan Sheet
Executive Summary
McNeil Consumer Healthcare expands a voluntary recall of its arthritis analgesic from five lots to all available lots following consumer reports of a moldy odor associated with the product. The Johnson & Johnson unit and FDA said Dec. 18 certain lots of the Tylenol Arthritis Pain product in 100-count bottles had traces of a chemical from treated wooden pallets, though all adverse events associated with the resulting odor have been temporary and non-serious. McNeil said it plans to move production to a new facility and reintroduce the product
You may also be interested in...
McNeil Expands Tylenol Recall As FDA Criticizes Firm's Response To AERs
McNeil Consumer Healthcare's reaction to signs of potentially contaminated packaging for OTC products including Tylenol raised FDA's ire and is now costing the firm an extensive product recall
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.